According to Saili Medical's announcement, revenue for the third quarter of 2026 was 147 million yuan, a year-on-year decrease of 46.37%; net loss was 8.178,600 yuan. Revenue for the first three quarters of 2026 was 490 million yuan, down 42.89% year on year; net loss was 56.0145 million yuan, and loss narrowed year on year; after deducting non-net loss of 553,045 million yuan. The decline in revenue was mainly affected by the expansion of collection and procurement, health insurance fee control, and the transfer of shares in some subsidiaries. The narrowing of losses was due to cost control, delisting of convertible bonds to reduce interest expenses and credit impairment loss accruals. As of September 30, 2026, the company's special securities account held 3.977,700 shares, accounting for 1.76% of the total share capital.

According to Saili Medical's announcement, revenue for the third quarter of 2026 was 147 million yuan, a year-on-year decrease of 46.37%; net loss was 8.178,600 yuan. Revenue for the first three quarters of 2026 was 490 million yuan, down 42.89% year on year; net loss was 56.0145 million yuan, and loss narrowed year on year; after deducting non-net loss of 553,045 million yuan. The decline in revenue was mainly affected by the expansion of collection and procurement, health insurance fee control, and the transfer of shares in some subsidiaries. The narrowing of losses was due to cost control, delisting of convertible bonds to reduce interest expenses and credit impairment loss accruals. As of September 30, 2026, the company's special securities account held 3.977,700 shares, accounting for 1.76% of the total share capital.